Evidence map›Paper›PMID 40524271›Full record

ArticleBiomarker research2025

Microbiome multi-omics analysis reveals novel biomarkers and mechanisms linked with CD etiopathology.

Gerard Serrano-Gómez, Francisca Yañez, Zaida Soler, Marc Pons-Tarin, Luis Mayorga, Claudia Herrera-deGuise, Natalia Borruel, Antonio Rodriguez-Sinovas, Marta Consegal, Isaac Manjón and 2 more

Abstract read
In one paragraph

Article in Biomarker research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Gerard Serrano-GómezMicrobiome Lab, Vall d'Hebron Institut de Recerca (VHIR), 119-129 pg Vall d'Hebron, Barcelona, 08035, Spain.
Francisca Yañez *Microbiome Lab, Vall d'Hebron Institut de Recerca (VHIR), 119-129 pg Vall d'Hebron, Barcelona, 08035, Spain.
Zaida Soler *Microbiome Lab, Vall d'Hebron Institut de Recerca (VHIR), 119-129 pg Vall d'Hebron, Barcelona, 08035, Spain.
Marc Pons-Tarin *Microbiome Lab, Vall d'Hebron Institut de Recerca (VHIR), 119-129 pg Vall d'Hebron, Barcelona, 08035, Spain.
Luis MayorgaMicrobiome Lab, Vall d'Hebron Institut de Recerca (VHIR), 119-129 pg Vall d'Hebron, Barcelona, 08035, Spain.
Claudia Herrera-deGuiseMicrobiome Lab, Vall d'Hebron Institut de Recerca (VHIR), 119-129 pg Vall d'Hebron, Barcelona, 08035, Spain.
Natalia BorruelMicrobiome Lab, Vall d'Hebron Institut de Recerca (VHIR), 119-129 pg Vall d'Hebron, Barcelona, 08035, Spain.
Antonio Rodriguez-SinovasCardiovascular Diseases Research Group, Department of Cardiology, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Marta ConsegalCardiovascular Diseases Research Group, Department of Cardiology, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Isaac ManjónMicrobiome Lab, Vall d'Hebron Institut de Recerca (VHIR), 119-129 pg Vall d'Hebron, Barcelona, 08035, Spain.
Sara Vega-AbellanedaMicrobiome Lab, Vall d'Hebron Institut de Recerca (VHIR), 119-129 pg Vall d'Hebron, Barcelona, 08035, Spain.
Chaysavanh ManichanhMicrobiome Lab, Vall d'Hebron Institut de Recerca (VHIR), 119-129 pg Vall d'Hebron, Barcelona, 08035, Spain. cmanicha@gmail.com.

Funding

Agència de Gestió d'Ajuts Universitaris i de Recerca 2021 SGR 00459Agencia Nacional de Investigación y Desarrollo 72190278Instituto de Salud Carlos III FI21/00262Instituto de Salud Carlos III PI20/00130
6 · The paper itself

Abstract

backgroundThe gut microbiome plays a key role in the development of inflammatory bowel disease (IBD), as imbalances in microbial composition are associated with immune dysfunction. However, the specific mechanisms by which certain microorganisms contribute to this process remain unclear.

methodsHere, we employed a multi-omics approach on fecal samples to identify novel microbiome markers and elucidate mechanisms underlying IBD. Shotgun metagenomics was applied to 212 samples (850 in total with validation cohort), shotgun metatranscriptomics to 103 samples and metabolomics to 105 samples. Machine learning techniques were used to predict disease and the three omics data were integrated to propose a mechanistic role of the microbiota.

resultsMetagenomic analysis identified Crohn's disease (CD)-specific microbiome signatures, including a panel of 20 species that achieved a high diagnostic performance, with an area under the ROC curve (AUC) of 0.94 in an external validation set. Metatranscriptomic analysis revealed significant alterations in microbial fermentation pathways in CD, but not in ulcerative colitis (UC), highlighting disruptions that explain the depletion of butyrate-a key anti-inflammatory metabolite-observed in metabolomics analysis. Integrative multi-omics analyses further identified active virulence factor genes in CD, predominantly originating from the adherent-invasive Escherichia coli (AIEC). Notably, these findings unveiled novel mechanisms, including E. coli-mediated aspartate depletion and the utilization of propionate, which drives the expression of the ompA virulence gene, critical for bacterial adherence and invasion of the host's macrophages. Interestingly, these microbiome alterations were absent in UC, underscoring distinct mechanisms of disease development between the two IBD subtypes.

conclusionsIn conclusion, our study not only identifies promising novel biomarkers with strong diagnostic potential, which could be valuable in challenging clinical scenarios, but also offers an integrated multi-omics perspective on the microbial mechanisms underlying inflammation and virulence in Crohn's disease.

Indexed as

Adherent-invasive Escherichia coliInflammatory bowel diseaseMicrobiomeMulti-omicsVirulence gene

Identifiers

PMID40524271
PMCPMC12172205

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.